The benefits of ICI therapy have been replicated in multiple cancers including head and neck cancer, melanoma, bladder cancer, etc. Mechanistically, ICIs unblock the host’s adaptive immune response using monoclonal antibodies tailored toward ligands or receptors with inhibitory motifs like PD-1, PD-L1, and CTLA-4. The gene discussed is CTLA4; the disease is cancer.